- Tytuł:
- Is It Time for Ocrelizumab Extended Interval Dosing in Relapsing Remitting MS? Evidence from An Italian Multicenter Experience During the COVID-19 Pandemic
- Autorzy:
- Źródło:
- Neurotherapeutics: The Journal of the American Society for Experimental Neurotherapeutics. 19(5):1535-1545
Czasopismo naukowe